Get the Stockscreener App
22.53
4.49%
-1.06
Denali Therapeutics Inc Stock (DNLI) Latest News
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - Marketscreener.com
Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa - Marketscreener.com
Where are the Opportunities in (DNLI) - Stock Traders Daily
Leerink Partnrs Has Negative Outlook of DNLI FY2025 Earnings - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Sees Significant Increase in Short Interest - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 6.2%Should You Sell? - MarketBeat
Zacks Research Has Bearish Estimate for DNLI FY2024 Earnings - MarketBeat
Denali Gains 26.6% in a Year: How Should You Play the Stock? - MSN
Denali Therapeutics Insiders Sold US$2.2m Of Shares Suggesting Hesitancy - Simply Wall St
What is Leerink Partnrs’ Forecast for DNLI FY2025 Earnings? - Defense World
Zacks Research Has Negative Outlook of DNLI FY2024 Earnings - Defense World
The Goldman Sachs Group Lowers Denali Therapeutics (NASDAQ:DNLI) Price Target to $40.00 - MarketBeat
Alzheimer's Disease Therapeutics Market to Grow by USD 5.41 Billion (2024-2028), Novel Biomarker R&D Boosts Growth, with AI Driving Market TransformationTechnavio - The Malaysian Reserve
Denali Therapeutics Announces Upcoming Presentations on - GlobeNewswire
Revolutionary Brain Barrier Treatment for Hunter Syndrome Takes Center Stage at Major Medical Conference - StockTitan
The Goldman Sachs Group Has Lowered Expectations for Denali Therapeutics (NASDAQ:DNLI) Stock Price - Defense World
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 4.3%Time to Sell? - MarketBeat
How To Trade (DNLI) - Stock Traders Daily
Cantor Fitzgerald Weighs in on DNLI FY2025 Earnings - Defense World
Analysts Set Expectations for DNLI FY2025 Earnings - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Short Interest Update - Defense World
Short Interest in Denali Therapeutics Inc. (NASDAQ:DNLI) Grows By 5.1% - MarketBeat
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation - MSN
Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
JPMorgan Chase & Co. Purchases 14,324 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Denali Therapeutics sees cash runway into 2028 - MSN
Why Is Denali Therapeutics Stock Trading Higher On Wednesday? - Benzinga
Denali Therapeutics (NASDAQ:DNLI) Stock Price Up 9.8%Still a Buy? - MarketBeat
Denali Therapeutics' (DNLI) Outperform Rating Reaffirmed at William Blair - MarketBeat
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints - MSN
Denali Therapeutics Announces Key Anticipated 2025 - GlobeNewswire
Denali's Tividenofusp Alfa Earns FDA Breakthrough Status for Hunter Syndrome, BLA Filing Set for 2025 - StockTitan
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases - The Manila Times
Denali Therapeutics gets FDA breakthrough therapy designation for its treatment of hunter syndrome - MSN
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail - BioSpace
Denali Therapeutics CEO Ryan Watts sells $750,955 in stock By Investing.com - Investing.com Nigeria
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More - MSN
Denali Therapeutics director Steve Krognes sells $69,484 in stock By Investing.com - Investing.com Australia
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains (NASDAQ:DNLI) - Seeking Alpha
Denali Therapeutics' chief medical officer Carole Ho sells $308,290 in stock By Investing.com - Investing.com South Africa
HC Wainwright Has Positive Forecast for DNLI FY2026 Earnings - MarketBeat
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):